CL2011002652A1 - Composicion farmaceutica que comprende un compuesto derivado de n-({4-amino-3-[(trihalometil)sulfonil]fenil}sulfonil)-4-(piperazin-1-il)benzamida, un antioxidante calcogeno y un vehiculo lipidico; y su uso para tratar una enfermedad caracterizada por disfuncion apoptotica, tal como una enfermedad neoplasica. - Google Patents

Composicion farmaceutica que comprende un compuesto derivado de n-({4-amino-3-[(trihalometil)sulfonil]fenil}sulfonil)-4-(piperazin-1-il)benzamida, un antioxidante calcogeno y un vehiculo lipidico; y su uso para tratar una enfermedad caracterizada por disfuncion apoptotica, tal como una enfermedad neoplasica.

Info

Publication number
CL2011002652A1
CL2011002652A1 CL2011002652A CL2011002652A CL2011002652A1 CL 2011002652 A1 CL2011002652 A1 CL 2011002652A1 CL 2011002652 A CL2011002652 A CL 2011002652A CL 2011002652 A CL2011002652 A CL 2011002652A CL 2011002652 A1 CL2011002652 A1 CL 2011002652A1
Authority
CL
Chile
Prior art keywords
sulfonyl
disease
treat
pharmaceutical composition
trihalomethyl
Prior art date
Application number
CL2011002652A
Other languages
English (en)
Inventor
Nathaniel Catron
Michael Fickes
Cristina Fischer
Anthony R Haight
Katherien Heemstra
Yeshwant Sanzgiri
Eric Schmitt
Ping Tong
Geoff Zhang
Deliang Zhou
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CL2011002652A1 publication Critical patent/CL2011002652A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA COMPOSICIÓN FARMACÉUTICA QUE SE PUEDE SUMINISTRAR EN FORMA ORAL. QUE COMPRENDE A UN COMPUESTO INHIBIDOR DE LAS PROTEINAS DE LA FAMILIA BCL-2, POR EJEMPLO, ABT-263, UN ANTIOXIDANTE CALCÓGENO MÁS PESADO Y UN VEHÍCULO LIPIDICO SUSTANCIALMENTE NO ACUOSO, DONDE DICHO COMPUESTO Y DICHO ANTIOXIDANTE ESTÁN FORMANDO UNA SOLUCIÓN EN EL VEHÍCULO. LA COMPOSICIÓN ES APROPIADA PARA ADMINISTRAR POR VÍA ORAL A UN SUJETO QUE LA NECESITA PARA TRATAR UNA ENFERMEDAD CARACTERIZADA POR LA SOBREEXPRESIÓN DE UNA O MÁS PROTEÍNAS ANTIAPOPTÓTICAS DE LA FAMILIA BCL-2, POR EJEMPLO CÁNCER.  
CL2011002652A 2009-04-30 2011-10-25 Composicion farmaceutica que comprende un compuesto derivado de n-({4-amino-3-[(trihalometil)sulfonil]fenil}sulfonil)-4-(piperazin-1-il)benzamida, un antioxidante calcogeno y un vehiculo lipidico; y su uso para tratar una enfermedad caracterizada por disfuncion apoptotica, tal como una enfermedad neoplasica. CL2011002652A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17429909P 2009-04-30 2009-04-30
US28925409P 2009-12-22 2009-12-22

Publications (1)

Publication Number Publication Date
CL2011002652A1 true CL2011002652A1 (es) 2012-04-20

Family

ID=42732293

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002652A CL2011002652A1 (es) 2009-04-30 2011-10-25 Composicion farmaceutica que comprende un compuesto derivado de n-({4-amino-3-[(trihalometil)sulfonil]fenil}sulfonil)-4-(piperazin-1-il)benzamida, un antioxidante calcogeno y un vehiculo lipidico; y su uso para tratar una enfermedad caracterizada por disfuncion apoptotica, tal como una enfermedad neoplasica.

Country Status (24)

Country Link
US (1) US8728516B2 (es)
EP (1) EP2424499A1 (es)
JP (1) JP5788869B2 (es)
KR (1) KR20120027283A (es)
CN (1) CN102802605B (es)
AR (1) AR076511A1 (es)
AU (1) AU2010242926B2 (es)
BR (1) BRPI1014492A8 (es)
CA (1) CA2758596A1 (es)
CL (1) CL2011002652A1 (es)
CO (1) CO6470833A2 (es)
DO (1) DOP2011000325A (es)
EC (1) ECSP11011491A (es)
IL (1) IL215474A (es)
MX (1) MX2011011525A (es)
MY (1) MY160603A (es)
NZ (1) NZ596047A (es)
PE (1) PE20120642A1 (es)
RU (1) RU2530642C2 (es)
SG (1) SG175145A1 (es)
TW (2) TW201628601A (es)
UY (1) UY32601A (es)
WO (1) WO2010127193A1 (es)
ZA (1) ZA201107594B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8362013B2 (en) * 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
TWI471321B (zh) * 2009-06-08 2015-02-01 Abbott Gmbh & Co Kg Ｂｃｌ－２族群抑制劑之口服醫藥劑型
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
CN102695702A (zh) 2009-09-20 2012-09-26 雅培制药有限公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
CA2780177A1 (en) * 2009-12-22 2011-06-30 Abbott Laboratories Abt-263 capsule
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
US8716363B2 (en) 2011-09-28 2014-05-06 Globus Medical, Inc. Biodegradable putty compositions and implant devices, methods, and kits relating to the same
US10456413B2 (en) * 2016-03-02 2019-10-29 Medivir Aktiebolag Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine
CN112552348B (zh) * 2019-09-26 2023-03-17 北京桦冠生物技术有限公司 含硒化合物及其制备和应用
EP4054553A4 (en) * 2019-11-08 2023-11-29 Retina Foundation of the Southwest JOINTS AND IMPLANTS FOR THE TREATMENT OF EYE DISEASES
CN110963954A (zh) * 2019-12-16 2020-04-07 武汉轻工大学 一种硒代蛋氨酸衍生物的合成方法及硒代蛋氨酸制品

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) * 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
IL111004A (en) * 1993-09-30 1998-06-15 American Home Prod Oral formulations of rapamycin
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
AU692506B2 (en) * 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
US5759548A (en) * 1993-11-30 1998-06-02 Lxr Biotechnology Inc. Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
BE1011899A6 (fr) * 1998-04-30 2000-02-01 Ucb Sa Compositions pharmaceutiques gelifiables utilisables.
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
DE19913692A1 (de) 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
DE19929361A1 (de) 1999-06-25 2001-01-04 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
US20020055631A1 (en) * 2000-09-20 2002-05-09 Augeri David J. N-acylsulfonamide apoptosis promoters
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CZ20031902A3 (cs) * 2001-01-31 2004-07-14 Pfizer Products Inc. Etherové deriváty užitečné jako inhibitory isozymů PDE4
US20030105144A1 (en) * 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
DK1471887T3 (da) * 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
EP1480679B1 (en) * 2002-02-26 2007-05-23 Astrazeneca AB Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative
PE20030828A1 (es) * 2002-03-04 2003-11-04 Novartis Ag Composicion oftalmica que comprende ascomicina
US7030115B2 (en) * 2002-03-21 2006-04-18 Abbott Laboratories N-sulfonylurea apoptosis promoters
JO2479B1 (en) * 2002-04-29 2009-01-20 ميرك شارب اند دوم ليمتد Rates for the activity of the chemokine receptor of tetrahydrobranyl cycloneptil tetrahydrobredo predine
AU2003299659A1 (en) * 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7973161B2 (en) * 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US7790190B2 (en) * 2004-03-20 2010-09-07 Yasoo Health, Inc. Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid
FR2875409B1 (fr) * 2004-09-17 2010-05-07 Sanofi Aventis Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose
MX2007014049A (es) * 2005-05-12 2008-02-11 Abbott Lab Activadores de apoptosis.
CN1706371B (zh) 2005-05-27 2010-11-10 沈阳药科大学 一种高效的马蔺子素制剂及其制备方法
ATE544444T1 (de) 2005-10-11 2012-02-15 Yissum Res Dev Co Zusammensetzungen für die nasale abgabe
CN101346128B (zh) * 2005-10-25 2013-10-02 雅培制药有限公司 包含低水溶解度药物的配方及其使用方法
US20080085313A1 (en) * 2006-05-15 2008-04-10 Given Bruce D Methods and compositions for treatment of sleep apnea
EP1880715A1 (en) 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
CA2662320C (en) * 2006-09-05 2014-07-22 Abbott Laboratories Bcl inhibitors treating platelet excess
AU2007305423A1 (en) * 2006-09-28 2008-04-10 Follica, Inc. Methods, kits, and compositions for generating new hair follicles and growing hair
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
WO2008124878A1 (en) 2007-04-13 2008-10-23 Cryptopharma Pty Ltd Non-steroidal compounds
EP2620157A3 (en) * 2007-10-12 2013-10-16 Massachusetts Institute of Technology Vaccine nanotechnology
US20090098118A1 (en) * 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
WO2009073835A1 (en) 2007-12-06 2009-06-11 Abbott Laboratories Oral compositions of abt-263 for treating cancer
CN101220008B (zh) 2008-01-21 2011-04-27 中国科学院广州生物医药与健康研究院 化合物abt-263的合成方法
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
US8362013B2 (en) 2009-04-30 2013-01-29 Abbvie Inc. Salt of ABT-263 and solid-state forms thereof
US8728516B2 (en) 2009-04-30 2014-05-20 Abbvie Inc. Stabilized lipid formulation of apoptosis promoter
US20100278921A1 (en) * 2009-04-30 2010-11-04 Fischer Cristina M Solid oral formulation of abt-263
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2012101627A (ru) * 2009-06-18 2013-07-27 Эбботт Лэборетриз Стабильная суспензия лекарственного средства в виде наночастиц
CN102695702A (zh) * 2009-09-20 2012-09-26 雅培制药有限公司 用于治疗bcl-2蛋白相关疾病的abt-263晶体形式和溶剂化物
CN101798292A (zh) 2010-03-29 2010-08-11 无锡好芳德药业有限公司 ABT-263衍生的新型Bcl-2蛋白抑制剂的制备

Also Published As

Publication number Publication date
IL215474A0 (en) 2011-12-29
CA2758596A1 (en) 2010-11-04
SG175145A1 (en) 2011-11-28
EP2424499A1 (en) 2012-03-07
ZA201107594B (en) 2014-03-26
RU2011148516A (ru) 2013-06-10
RU2530642C2 (ru) 2014-10-10
UY32601A (es) 2010-12-31
JP2012525435A (ja) 2012-10-22
ECSP11011491A (es) 2011-12-30
MY160603A (en) 2017-03-15
AR076511A1 (es) 2011-06-15
AU2010242926A1 (en) 2011-11-10
NZ596047A (en) 2013-11-29
DOP2011000325A (es) 2011-11-15
JP5788869B2 (ja) 2015-10-07
US20100278905A1 (en) 2010-11-04
KR20120027283A (ko) 2012-03-21
TW201100125A (en) 2011-01-01
MX2011011525A (es) 2011-11-18
CN102802605B (zh) 2015-08-12
CO6470833A2 (es) 2012-06-29
BRPI1014492A2 (pt) 2016-04-05
CN102802605A (zh) 2012-11-28
PE20120642A1 (es) 2012-06-24
US8728516B2 (en) 2014-05-20
AU2010242926B2 (en) 2014-04-24
BRPI1014492A8 (pt) 2017-10-24
IL215474A (en) 2015-06-30
TW201628601A (zh) 2016-08-16
WO2010127193A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
CL2011002652A1 (es) Composicion farmaceutica que comprende un compuesto derivado de n-({4-amino-3-[(trihalometil)sulfonil]fenil}sulfonil)-4-(piperazin-1-il)benzamida, un antioxidante calcogeno y un vehiculo lipidico; y su uso para tratar una enfermedad caracterizada por disfuncion apoptotica, tal como una enfermedad neoplasica.
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
DOP2014000133A (es) Triazolopiridinas sustituidas
DOP2016000250A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
CO6640270A2 (es) Morfolinopirimidad y su uso en terapia
CU23615B7 (es) Forma cristalina gamma-d del clorhidrato de la ivabradina, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
GT200500360A (es) Compuestos organicos
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
CU20120084A7 (es) Compuestos derivados de triazolopiridina sustituidos como inhibidores de la quinasa mps-1 y compuestos intermediarios para su preparación
GT201300254A (es) Triazolopiridinas
DOP2012000006A (es) Agonista de gpr119
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CU20110213A7 (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo
CL2008000089A1 (es) Compuestos derivados de 2,4-pirimidinona condensada con un heterociclo, inhibidores de pde-4; composicion farmaceutica; combinacion farmaceutica; procedimiento de preparacion de los compuestos, utiles para tratar trastornos inmunes e inflamatorios.
ECSP12012338A (es) Triazolopiridinas sustituidas
CL2012002551A1 (es) Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor.
ECSP11011503A (es) Compuestos carboxamida y su uso como inhibidores de calpaína.
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias
CU20190029A7 (es) Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos
UY33305A (es) Compuestos heterocíclicos inhibidores de DGAT1
BR112014009760A2 (pt) análogos de ácido siálico, seu uso e composição farmacêutica e composição farmacêutica de liberação sustentada os compreendendo
ES2422877B1 (es) Combinación y composición para el tratamiento de obesidad
PA8789101A1 (es) Composición farmacéutica estable que comprende una sal de vinflunina hidrosoluble